TD Asset Management Inc. reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 20.8% during the second quarter, Holdings Channel reports. The institutional investor owned 98,977 shares of the life sciences company’s stock after selling 25,965 shares during the period. TD Asset Management Inc.’s holdings in Illumina were worth $17,174,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the stock. Acadian Asset Management LLC boosted its stake in Illumina by 48.2% in the first quarter. Acadian Asset Management LLC now owns 23,505 shares of the life sciences company’s stock valued at $4,012,000 after buying an additional 7,649 shares in the last quarter. American Capital Management Inc. boosted its stake in Illumina by 1.6% in the first quarter. American Capital Management Inc. now owns 247,135 shares of the life sciences company’s stock valued at $42,171,000 after buying an additional 3,790 shares in the last quarter. Advocacy Wealth Management Services LLC bought a new stake in Illumina during the first quarter valued at approximately $102,000. Mn Services Vermogensbeheer B.V. boosted its stake in Illumina by 3.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 3,918 shares of the life sciences company’s stock valued at $625,000 after buying an additional 147 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Illumina by 129.5% in the first quarter. Nationwide Fund Advisors now owns 92,650 shares of the life sciences company’s stock valued at $15,810,000 after buying an additional 52,284 shares in the last quarter. 93.81% of the stock is owned by hedge funds and other institutional investors.

Illumina, Inc. (NASDAQ ILMN) opened at 194.25 on Friday. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $199.95. The company has a 50-day moving average price of $179.63 and a 200-day moving average price of $173.73. The stock has a market capitalization of $28.36 billion, a price-to-earnings ratio of 38.97 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the prior year, the company earned $0.86 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/13/td-asset-management-inc-sells-25965-shares-of-illumina-inc-ilmn.html.

Several equities research analysts recently commented on the company. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Vetr cut Illumina from a “strong-buy” rating to a “hold” rating and set a $202.18 price target for the company. in a report on Wednesday, August 2nd. Barclays PLC reiterated an “equal weight” rating and issued a $150.00 price objective on shares of Illumina in a research report on Wednesday. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Finally, Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and increased their price objective for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. Illumina presently has a consensus rating of “Hold” and an average price target of $177.01.

In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $195.00, for a total value of $1,950,000.00. Following the completion of the transaction, the senior vice president now directly owns 76,585 shares of the company’s stock, valued at approximately $14,934,075. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the transaction, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 134,010 shares of company stock valued at $23,946,015. 1.60% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.